# Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors

> **NCT05150457** · PHASE1 · UNKNOWN · sponsor: **Binacea Pharma, Inc.** · enrollment: 48 (estimated)

## Conditions studied

- Refractory Solid Tumors

## Interventions

- **DRUG:** BNA035

## Key facts

- **NCT ID:** NCT05150457
- **Lead sponsor:** Binacea Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-08
- **Primary completion:** 2023-11
- **Final completion:** 2025-11
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2022-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05150457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05150457, "Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05150457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*